Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Obinutuzumab may also reduce the risk of immune-related conditions from treatment. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the protein that signals cancer cells to multiply. Giving glofitamab in combination with pirtobrutinib may be safe, tolerable and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Oczekiwana długość życia co najmniej 12 tygodni
- •Ogólny stan zdrowia pozwalający na udział w badaniu
- •Wcześniejsze leczenie chłoniaka płaszcza - choroba wróciła lub nie reagowała na co najmniej jedno poprzednie leczenie
- •Widoczne guzy w badaniach obrazowych (co najmniej 1,5 cm)
- •Dostęp do próbki tkanki z czasu postępu choroby
- •Wystarczające parametry krwi: hemoglobina ≥9 g/dL, neutrofile ≥1,0 x 10⁹/L, płytki ≥50-75 x 10⁹/L
- •Prawidłowa funkcja wątroby: bilirubina ≤1,5 x norma, AST i ALT ≤2,5 x norma
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
University of California, Davis
Davis, United States
University of California, Los Angeles
Los Angeles, United States
University of California, San Francisco
San Francisco, United States
Trial contact
UCSF Hematopoietic Malignancies Clinical Trial Recruitment
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.